title: Jieduquyuziyin prescription suppresses IL-17 production and Th17 activity in MRL/lpr mice by inhibiting expression of Ca(2+)/calmodulin-dependent protein kinase-4.
abstract: Jieduquyuziyin prescription (JP) is a traditional Chinese medicinal (TCM) formula which has been demonstrated to be effective for systemic lupus erythematosus (SLE) treatment as an approved hospital prescription for many years in China. But its mechanism of action in combating this disease is largely unknown. Our previous studies showed that JP can slow disease progression without producing significant toxic side effects. We treated MRL/lpr mice with JP to ascertain if JP could improve SLE by the suppression of Ca(2+)/calmodulin-dependent protein kinase-4 (CaMK4) expression. We investigated the role of JP in a model of SLE in MRL/lpr mice, and identified the possible mechanism of action. Mice were divided randomly into four groups: control, model, and two treatment groups. Sections of renal tissue were stained with hematoxylin and eosin (H&E). Histopathologic changes in the kidney were evaluated by light microscopy. T-helper (Th)17 cells were analyzed by flow cytometry. mRNA levels of interleukin (IL)-17, CaMK4, and RORγt were measured by reverse transcription polymerase chain reaction (RT-PCR). CaMK4 expression was assessed by Western blotting. The results showed that the percentages of Th17, IL-17, and RORγt in mice treated with JP were decreased remarkably compared to the model group (p < 0.05). Interestingly, a high CaMK4 expression was observed in the SLE mice, which was inhibited by JP. These results suggest that CaMK4 activity was increased in T cells from MRL/lpr mice compared with the control group. Our findings support the conclusion that the effects of JP on MRL/lpr mice may involve the regulation of CaMK4 overexpression in MRL/lpr mice.
authors.affiliation: Zhejiang Chinese Medical University College of Life Science, Hangzhou, China.
authors.forename: Bingjie
authors.initials: B
authors.lastname: Shui
authors.forename: Weibiao
authors.initials: W
authors.lastname: Xia
authors.forename: Chengping
authors.initials: C
authors.lastname: Wen
authors.forename: Xinghong
authors.initials: X
authors.lastname: Ding
mesh_terms: D000818:Animals; D054734:Calcium-Calmodulin-Dependent Protein Kinase Type 4 / Q000235:genetics / Q000378:metabolism*; D002454:Cell Differentiation; D004353:Drug Evaluation, Preclinical; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004794:Enzyme Repression / Q000187:drug effects; D005260:Female; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D020381:Interleukin-17 / Q000096:biosynthesis*; D007668:Kidney / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D019463:Mice, Inbred MRL lpr; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology*
chemical_list: D004365:Drugs, Chinese Herbal; D007166:Immunosuppressive Agents; D020381:Interleukin-17; C000604362:jieduquyuziyin; D054734:Calcium-Calmodulin-Dependent Protein Kinase Type 4; C517685:Camk4 protein, mouse
references.citation: Trends Immunol. 2008 Dec;29(12):600-7
references.pmid: 18930438
references.citation: J Immunol. 2011 Dec 1;187(11):5500-4
references.pmid: 22031763
references.citation: Transpl Int. 2014 Apr;27(4):408-15
references.pmid: 24410777
references.citation: J Biol Chem. 2011 Dec 16;286(50):43437-46
references.pmid: 22025620
references.citation: N Engl J Med. 2011 Dec 1;365(22):2110-21
references.pmid: 22129255
references.citation: J Clin Immunol. 2010 Mar;30(2):185-95
references.pmid: 20177959
references.citation: Annu Rev Immunol. 2009;27:485-517
references.pmid: 19132915
references.citation: Arthritis Rheum. 2012 Nov;64(11):3494-7
references.pmid: 22736339
references.citation: J Clin Immunol. 2010 Mar;30(2):221-5
references.pmid: 20107878
references.citation: Rheumatol Int. 2012 Apr;32(4):949-58
references.pmid: 21243492
references.citation: Clin Rev Allergy Immunol. 2013 Apr;44(2):114-20
references.pmid: 22231516
references.citation: Arthritis Rheum. 2011 Feb;63(2):523-9
references.pmid: 20954187
references.citation: Clin Rheumatol. 2013 Jul;32(7):1045-52
references.pmid: 23526148
references.citation: Clin Rheumatol. 2013 Jul;32(7):1071-3
references.pmid: 23456414
references.citation: Mol Biol Rep. 2013 Jan;40(1):391-9
references.pmid: 23054011
references.citation: J Clin Invest. 2014 May;124(5):2234-45
references.pmid: 24667640
references.citation: Clin Rheumatol. 2012 Mar;31(3):483-91
references.pmid: 22042490
references.citation: PLoS One. 2014 Feb 05;9(2):e88223
references.pmid: 24505438
references.citation: Rheumatol Int. 2014 Mar;34(3):445-6
references.pmid: 23263497
references.citation: Arthritis Res Ther. 2014 Mar 06;16(2):R62
references.pmid: 24598455
references.citation: J Biol Chem. 2012 Feb 10;287(7):4715-25
references.pmid: 22184122
references.citation: Z Rheumatol. 2009 May;68(3):205-8, 210-13
references.pmid: 19399510
references.citation: Arthritis Res Ther. 2010;12(4):R150
references.pmid: 20653937
references.citation: Inflammation. 2012 Jun;35(3):1119-31
references.pmid: 22219048
references.citation: Clin Rev Allergy Immunol. 2013 Jun;44(3):229-41
references.pmid: 22826112
references.citation: J Immunol. 2012 Oct 1;189(7):3490-6
references.pmid: 22942433
references.citation: Mucosal Immunol. 2014 May;7(3):521-32
references.pmid: 24064669